In a prospective observation study published in the journal Clinical Lymphoma Myeloma and Leukemia, researchers from Phramongkutklao College of Medicine in Bangkok, Thailand investigated clinical features, presentations, outcomes, complications, and cytogenetic risk stratification in Thai AML patients.

Hematopoietic stem cell transplantation (HSCT) is an intervention that can be employed when treating patients with AML, effectively reducing the rate of relapse and enhancing patients’ overall survival rate. Unfortunately, due to a lack of accessibility in Thailand as a result of few transplantation centres across the country combined with limited patient quotas, few AML patients receive HSCT treatment. This study sought to examine factors associated with AML survival in the Thai population.

The outcome of low HSCT intervention rates is that the patient population has an overall survival (OS) comparable to that of elderly patients in developing countries. This patient population commonly experiences rapidly progressive bone marrow failure, and in developing countries such as Thailand, the 5-year OS rate currently ranges between 48-67%. Further, the authors demonstrate the importance of determining subtype of AML such as acute promyelocytic leukemia (APL) and Philadelphia-chromosome positive AML in the Thai population. This study demonstrates the important findings and associations of AML in the Thai population. 

Reference:

Chinadol Wanitpongpun, Eakkapol Utchariyaprasit, Weerapat Owattanapanich, Adisak Tantiworawit, Ekarat Rattarittamrong, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamanee, Pirun Saelue, Chantiya Chanswangphuwana, Chantana Polprasert, Chajchawan Nakhakes, Wasithep Limvorapitak, Nonglak Kanitsap, Kannadit Prayongratana, Chantrapa Sriswasdi. Types, Clinical Features and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-year Prospective Multicenter Study from Thai Acute Leukemia Study Group (TALSG). Clinical Lymphoma Myeloma and Leukemia. 2021.

https://doi.org/10.1016/j.clml.2021.03.004.

Tags: study, myeloma, Outcomes, Patients, Lymphoma, Survival, leukemia, clinical, acute, thailand, 3 years, prospective